Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Evgen Pharma Plc LSE:EVG London Ordinary Share GB00BSVYN304 ORD 0.25P
  Price Change % Change Share Price Shares Traded Last Trade
  0.00 0.00% 17.88 42,173 08:00:00
Bid Price Offer Price High Price Low Price Open Price
17.75 18.00 17.88 17.88 17.88
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology -3.12 -2.74 24.0
Last Trade Time Trade Type Trade Size Trade Price Currency
08:42:26 O 42,173 17.78 GBX

Evgen Pharma (EVG) Latest News

More Evgen Pharma News
Evgen Pharma Takeover Rumours

Evgen Pharma (EVG) Share Charts

1 Year Evgen Pharma Chart

1 Year Evgen Pharma Chart

1 Month Evgen Pharma Chart

1 Month Evgen Pharma Chart

Intraday Evgen Pharma Chart

Intraday Evgen Pharma Chart

Evgen Pharma (EVG) Discussions and Chat

Evgen Pharma (EVG) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
2019-06-26 07:42:2817.7842,1737,498.36O
View all Evgen Pharma trades in real-time

Evgen Pharma (EVG) Top Chat Posts

DateSubject
26/6/2019
09:20
Evgen Pharma Daily Update: Evgen Pharma Plc is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker EVG. The last closing price for Evgen Pharma was 17.88p.
Evgen Pharma Plc has a 4 week average price of 17p and a 12 week average price of 15.50p.
The 1 year high share price is 28.50p while the 1 year low share price is currently 13p.
There are currently 132,646,263 shares in issue and the average daily traded volume is 110,589 shares. The market capitalisation of Evgen Pharma Plc is £23,710,519.51.
29/3/2019
18:50
ardinno: So, at the end of a relatively rollercoaster week, the share price is back to where it was before the results were released. I’m in this for the long-haul, but can’t pretend I’m not somewhat disheartened by the collective shrug the market has given Evgen this week.
23/3/2019
10:40
researchanalyst1: Hardman & Co., the London-based, industry-renowned research analysts, brand themselves as the ‘Gold-standard for research and analysis for ambitious businesses’. Wow! What a powerful statement. And to boot, they’ve won countless awards as a result of their impeccable approach to selecting winning investments; a reflection of their in-depth knowledge and reputation for integrity. So, would Evgen Pharma fit their profile of an ‘ambitious business’? Answer: Yes. And would Evgen Pharma fit their profile of a ‘winning investment’? Answer: Yes. Released only 7 months ago, here’s what they think of the company: “Evgen’s lead candidate SFX-01 is being assessed in Phase II trials for SAH and breast cancer, both strategic entry portals for other uses in neurology and oncology. It is probably too early to draw any firm conclusions, but the interim data provides reassurance that the trial may hit its primary end-point of safety, tolerability and signs of efficacy in this hard-to-treat population. Despite these encouraging data, the share price did not respond as expected. As with all drug development companies, there is a risk that products will fail in clinical trials. However, Sulforaphane has been through a number of encouraging clinical trials despite its stability and dosing limitations. Therefore, coupled with two potential targets, Evgen’s risk profile is arguably reduced. SFX-01 would be entering multi-billion-dollar global markets that are currently unsatisfied. There is also potential to use Sulforaphane in other indications. Evgen intends to out-license its drugs to the pharma majors for commercialisation. Despite some share price appreciation recently, the enterprise value afforded to Evgen by the market does not reflect properly the development stage of SFX-01, and lower than usual risk profile.” The share price, at the time of that publication, was 21p. Fellow investors, I have a good feeling about this one.
19/3/2019
08:09
soultrading: The share price here could explode upwards. Everything seems to sound very positive indeed.
06/3/2019
19:25
l0ngterm: The ceo has said repeatedly let the science do the talking, not the PR team. So investors that look for news will get bored, chase something else etc. Others were expecting a spike or rise into the results. So not really surprised at where we are from a share price perspective.
02/1/2019
17:00
timbo003: >>>spmc, had the response rate been 30%, I suspect the share price would be multiples of where it is now, I am quite happy with where the price is now, as it provides an opportunity to top up at a price which does not really reflect the risk reward profile IMO >>>>>aoifesweb, as a Surrey based shareholder, I think it was probably beyond the call of duty to attend an AGM in Manchester, especially as the Research Symposium was due to be held in London a couple of months after the AGM.
02/1/2019
15:13
spmc: You can tell the 20% we hit on the interim update wasn’t considered good enough by the way the share price reacted. We dropped from 25.3p down to 17p. The market know’s the margins are so fine now it’s basicaly a coin toss for the final readout. I would have been much happier if their had been 30% plus responders as there would now be more room for error.
13/11/2018
10:52
aoifesweb: This is my favourite bit ‘Analysts at Northland Capital currently have a price target of 113p on the shares, providing over 500% upside from today’s share price. The global market opportunity in metastatic breast cancer alone for SFX-01 is estimated to be between US$6 to US$7bn/year, with this in mind it’s easy to see why analysts expect the shares perform so well.‘: Https://uk-investor.com/2018/11/12/could-evgen-pharma-lonevg-make-you-a-millionaire-in-2019/
13/6/2018
12:14
teddy boy1: There should be a law against what has happened this morning ;the way the share price was systematically taken down to encourage more sales.This share is definitely being "worked " and the bottom line is that all the shorters and the market makers have made themselves a shed load of money over the past 3 days- and this is on a GOOD trial update ! Think of what would have happened if the news had been bad! On second thoughts the share price would not have been too much different ,left to its own devices. Anyhow this is AIM , and this is how things are ! Perhaps companys such as EVGEN and IDP with very tightly held shares should be avoided like the plague as they are prime candidates for manipulation . With such companys;until they have proved themselves 100 per cent, the seeds of doubt will be sown and before we know where we are the share price has been worked down until the share price bears no resemblance to its true value. This is a real pity as I have not read anything myself which would encourage me to dispose of my shares as, as far as I am concerned ,Evgen Pharma has a very bright future .However ,it could still be many months/years before we are allowed a TRUE share price which values the company for what it is worth and not what some individuals CAUSE it to be, in the quest to make some easy money for themselves, over and over again! Anyone else agree with my sentiments?
11/6/2018
19:57
teddy boy1: It is pleasing to see that Northland Capital having seen the trial update,are still of the opinion that the share price target should remain unchanged at 113P. In my opinion there has been a certain amount of share price manipulation to-day as there has been more buying than selling. If past experience is anything to go by, I will be very surprised if the price does not show a nice "correction" tomorrow. Things are still on course for Evgen although it will be another 6 months before this has been one hundred per cent proved. In the meantime I am still more that happy to have this share in my portfolio!
03/5/2018
15:04
bernymadoff: Only idiots look at the rise and fall of a share price to determine whether they should invest and at what price. It wasn't long ago that institutions were paying 37p on IPO to get exposure to the drugs EVG are testing. Since then many of them have continued to buy and they currently hold 55% or so of the whole company. Institutional investment is one of the major ingredients I look for when deciding to invest anywhere. It gives you a level of confidence knowing that experts have evaluated the company to a degree that lay people could not achieve. Big plus there. Then there is the performance of the company. To date EVG have not put a foot wrong and all their drug trials have exceeded market expectations. Yet the market has not assigned any value to the progress the company has made since IPO in October 2015. Like many other pre-revenue AIM companies with great potential it has been at the mercy of the spivs in the city who have manipulated the share price down so that they can screw the company in the knowledge that it is dependent on placings to see it through to commercialisation. There is a wealth of information out there showing just how disconnected the share price is to the actual potential of EVG. For me that's where the opportunity lies. The greater the disconnect the greater the correction (in fact in these cases the correction often overshoots to the overvalued side). The other big thing the company has going for it is that it is funded through to the end of the year by which point it may well have landed a licensing or JV deal if the results due this quarter and then again at the end of the year are any good. Certainly the CEO has been dropping hints to that effect in recent rns'. You can choose to play the swings or you can hold for the big prize that the evidence suggests is now within grasp.
Evgen Pharma share price data is direct from the London Stock Exchange
Your Recent History
LSE
EVG
Evgen Phar..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20190627 00:52:54